Advertisement

Topics

Latest "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" News Stories - Page: 20

22:14 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" found in our extensive news archives from over 250 global news sources.

More Information about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 for you to read. Along with our medical data and news we also list Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Companies for you to search.

Showing "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" News Articles 476–500 of 36,000+

Monday 18th March 2019

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to...   


Latest Research Continues to Validate the Etiometry Platform’s Impact on Critical Care

The American College of Cardiology Conference unveiled a first-of-its kind study evaluating the effect of a digital health platform based on registry data. The abstract presented by Dr. Mary K. Olive, Pediatric Cardiac Critical Care Physician at C.S. Mott Children’s Hospital, is now a part of the growing evidence associating Etiometry’s...

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase

The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also...    


Transgene Secures a €20 Million Revolving Credit Facility with Natixis

Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that it has secured a €20 million revolving credit facility with Natixis, the French Corporate and Investment bank. The credit facility will have ...

Generics Firms Improved Chances Of Winning Pre-ANDA Meetings For Complex Drugs Last Year

FDA officials said manufacturers of complex generic drugs submitted more approvable requests for pre-submission meetings for FY 2018. Official also...   

Haemato will eine unveränderte Dividende ausschütten

Die Haemato AG aus Berlin (ISIN: DE0006190705) will für das Geschäftsjahr 2018 eine unveränderte Dividende in Höhe von 0,30 Euro je Aktie ausschütten. Im Vorjahr wurden ebenfalls 0,30 Euro ausbezah...

CURE Media Group Named the 2019 Ovarian Cancer Heroes®

CURE Media Group’s flagship product, CURE® magazine, which reaches over a million patients, survivors and caregivers and is dedicated to providing cancer updates, announced the 2019 Ovarian Cancer Heroes® who have made a difference in the field. The event was held during the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. This...

Haemato: Gewinn sinkt, Dividende bleibt konstant

Von der Berliner Haemato AG wurden am Montag vorläufige Zahlen für das vergangene Jahr vorgelegt. Unternehmensangaben zufolge sei der Umsatz 2018 von 289,4 Millionen Euro auf 274,1 Millionen Euro g...

Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients

DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam),...

Los Angeles Conference Brings Together World Leaders in Aesthetic Surgery to Host Most Advanced Aesthetics Industry Event – March 21-24, 2019

Multi-Specialty Cosmetic Academy (MCA), a California-based aesthetic medical educational organization, announces the 2nd Annual LA-MCA Meeting (Los Angeles Multi-Specialty Cosmetic Academy), which will be held March 21-24, 2019, at the Four Seasons Hotel, Doheny Drive, Los Angeles, CA. LA-MCA 2019 is comprised of over 65 leading physician speakers...

Biotech-Highflyer Amarin legt nach: Big Pharma schaut (noch) zu

Novartis, Pfizer, Novo Nordisk: Die Biotech-Schmiede Amarin wurde zuletzt mit einigen großen Pharma-Konzernen als Übernahmekandidat in Verbindung gebracht. Hauptursache für die Gerüchte ist Vascepa...

Oasmia Pharmaceutical AB: Oasmia announces a prospectus regarding admission to trading of new shares

Oasmia Pharmaceutical AB (publ) ("Oasmia" or the "Company") has prepared a prospectus regarding the admission to trading of the 22,948,535 shares in the Company that were issued in the directed iss...

HAEMATO AG: Preliminary Results 2018

DGAP-News: HAEMATO AG / Key word(s): Preliminary Results 18.03.2019 / 15:14 The issuer is solely responsible for the content of this announcement. Corporate News of HAEMATO AG: HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 27...

USDM Life Sciences Presents Best Practices for Managing GxP Compliance in the Oracle Cloud at Modern Business Experience in Las Vegas

USDM and Oracle are evolving GxP compliance in the cloud. SANTA BARBARA, Calif. (PRWEB) March 18, 2019 For more than 15 years, USDM Life Sciences and Oracle have partnered together to develop solutions that allow life science companies to easily comply with FDA 21 CFR Part 11 and EMA EudraLex Volume 4 Annex 11 regulatory requirements. USDM’s Cloud Assurance™ is a managed service delivering en...

AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock

MAYNARD, Mass., March 18, 2019 (GLOBE NEWSWIRE) Read more...

Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

SOUTH SAN FRANCISCO, Calif., March 18, 2019 (GLOBE NEWSWIRE) Read more...

Genesis Healthcare, Inc. 2018 Q4 - Results - Earnings Call Slides

Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q4 2018 Results - Earnings Call Transcript

DGAP-News: HAEMATO AG: Vorläufiges Ergebnis 2018 (deutsch)

HAEMATO AG: Vorläufiges Ergebnis 2018 DGAP-News: HAEMATO AG / Schlagwort(e): Vorläufiges Ergebnis HAEMATO AG: Vorläufiges Ergebnis 2018 18.03.2019 / 15:14 Für den Inhalt der Mitteilung ist der Emit...

Diagnostics Data Analytics Company Diaceutics to List on London Stock Exchange

Company seeking £53M IPO on London Stock Exchange junior market, AIM (Alternative Investment Market) Diaceutics expects the addressable market for its specific services to grow to US$2.5BN by 2023 Diaceutics plc, a revenue-generating and profitable diagnostics data analytics and implementation services company which ...

ACG expands in Latin American with announcement of its Brazilian capsule plant

ACG announces plans to grow its Latin American presence with its newest capsule production plant in Brazil, as it continues to expand its facilities in Asia-Pacific and Europe.

ACG announces the opening of its Brazil-based capsule plant

ACG announces plans to grow its Latin American presence with its newest capsule production plant in Brazil, as it continues to expand its facilities in Asia-Pacific and Europe.

Human medicines European public assessment report (EPAR): Halimatoz, adalimumab, Hidradenitis Suppurativa,Psoriasis,Arthritis, Juvenile Rheumatoid,Uveitis,Arthritis, Rheumatoid,Spondylitis, Ankylosing,Arthritis, Psoriatic, Date of authorisation: 26/07/201

Human medicines European public assessment report (EPAR): Halimatoz, adalimumab, Hidradenitis Suppurativa,Psoriasis,Arthritis, Juvenile Rheumatoid,Uveitis,Arthritis, Rheumatoid,Spondylitis, Ankylosing,Arthritis, Psoriatic, Date of authorisation: 26/07/2018, Revision: 2, Status: Authorised

Metrohm and B&W Tek to take Raman spectroscopy to the next level

The acquisition of B&W Tek LLC by Swiss Metrohm AG in July 2018 creates one of the largest solution providers for applied Raman spectroscopy. Two technology leaders in the field of Raman spectroscopy join forces, and customers all over the world will benefit: That is the key message that Metrohm and...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks